Stock listing
Immunovant, Inc.
Selected listing: IMVT · NASDAQ · USD · US
Immunovant, Inc. (NASDAQ:IMVT), Health Technology. Latest release Sep 23, 2026: Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402…
- Ticker
- NASDAQ:IMVT
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
About Immunovant, Inc.
Immunovant, Inc. is a public company traded under the ticker IMVT in the American market. Immunovant focuses on developing innovative therapies for autoimmune diseases.
Latest news from Immunovant, Inc.
Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
September 23, 2026
Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
September 23, 2026
Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
July 23, 2026
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026
May 20, 2026
Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026
May 11, 2026